Hock Meng Tay

Grand Venture Technology seeks to raise $9.74m in Catalist IPO

GVT offers manufacturing solutions and services for the semiconductor, analytical life sciences, electronics and other industries. It currently operates in Singapore, Malaysia and China.

Decoding CapitaLand’s $8b purchase of Ascendas-Singbridge

We take a look at the overall value proposition of the deal and how it aligns with Singapore’s vision of emerging as a global fund management hub.

SGX to attract niche listings from REITs, healthcare, F&B sectors in 2019: PwC report

In 2018, REITs and BTs led the IPO pack on the Singapore exchange accounting for 57.7 per cent in value of all offerings.

Did Indonesia’s KinerjaPay command a steep valuation in its $200m fundraising?

DEALSTREETASIA takes a deeper look at the deal fineprint, business metrics and financial ratios of KinerjaPay.

Reebonz Holding makes tepid Nasdaq debut

Reebonz Holding is the entity formed after the merger of Singapore’s online luxury marketplace Reebonz with Nasdaq-listed DOTA.

Malaysian theme parks group Sim Leisure seeks Catalist listing

The group seeks to raise invest the IPO proceeds to fund a new park in China’s Shandong province apart from expanding its existing theme park operations.

2018 saw SE Asia’s VC firms announce over $2b in additional dry powder

The surge was driven by expanding purse sizes of corporate venture capital (CVC) units and the entry of bigger first-time funds.

Indonesia surpasses Singapore to conduct most IPOs in 2018

Public listings in Singapore hit a five-year low with 15 companies raising a total of about $523 million in 2018, while Indonesia recorded a new high by raising a total of $1.1 billion from 57 listings during the year.

Singapore dominated dealmaking in Southeast Asia this year: Duff & Phelps

Singapore maintained its position as Southeast Asia’s leading deal hub this year as it oversaw 857 transactions spanning merger and acquisitions (M&A), private equity/venture capital and IPOs worth $106.2 billion.

Medical tech firm Biolidics set for SGX Catalist debut

The company seeks to use its public-listing status to expand its clinical services applications and customer segment.